Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.

Détails

ID Serval
serval:BIB_B9074F682569
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma.
Périodique
Oral oncology
Auteur⸱e⸱s
Modesto A., Blanchard P., Tao Y.G., Rives M., Janot F., Serrano E., Benlyazid A., Guigay J., Ferrand F.R., Delord J.P., Bourhis J., Daly-Schveitzer N.
ISSN
1879-0593 (Electronic)
ISSN-L
1368-8375
Statut éditorial
Publié
Date de publication
08/2013
Peer-reviewed
Oui
Volume
49
Numéro
8
Pages
830-834
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To analyze the clinical features, treatment modalities and outcome of patients treated for a localized esthesioneuroblastoma (ENB).
Forty-three consecutive patients with biopsy proven ENB treated at two referral cancer centers between 1998 and 2010 were retrospectively reviewed.
Overall, 5 patients had stage A disease, 13 stage B, 16 stage C and 9 stage D according to the modified Kadish classification. Neo-adjuvant chemotherapy was performed in 23 patients leading to a 74 % response rate. Thirty-one patients were treated by surgery. Thirty-nine patients (90.6%) underwent radiation therapy. Twelve patients received bilateral cervical lymph node irradiation (LNI). After a median follow-up of 77 months, the 5-year overall and progression free survival were 65% and 57%. Twelve patients (28%) had a locoregional relapse leading to 10 ENB-related deaths. The major prognostic factor was the modified Kadish stage with a 3-year survival for stage A-B, C and D of 100%, 48% and 22% respectively (p < 0.0001). Two (9%) isolated cervical lymph node relapses occurred among staged B and C patients treated without elective LNI and none after elective or adjuvant LNI.
The high risk of locoregional failure in ENB justifies the use of multimodal therapy. Induction chemotherapy leads to a high response rate. Elective LNI might prevent regional failure in locally advanced disease.
Mots-clé
Adolescent, Adult, Aged, Aged, 80 and over, Child, Esthesioneuroblastoma, Olfactory/diagnosis, Esthesioneuroblastoma, Olfactory/therapy, Female, Humans, Male, Middle Aged, Survival Analysis, Treatment Outcome, Young Adult, Concurrent chemotherapy, Elective neck irradiation, Esthesioneuroblastoma, Intensity Modulated Radiation Therapy, Neo-adjuvant chemotherapy, Olfactory neuroblastoma
Pubmed
Web of science
Création de la notice
16/10/2018 15:26
Dernière modification de la notice
20/08/2019 16:27
Données d'usage